Statistical methods for studying disease subtype heterogeneity

Statistics in Medicine

Volumn 35, Issue 5, 2016, Pages 782-800

  Wang, Molin ^a,b   Spiegelman, Donna ^a   Kuchiba, Aya ^c   Lochhead, Paul ^e   Kim, Sehee ^d   Chan, Andrew T ^b,e   Poole, Elizabeth M ^b   Tamimi, Rulla ^a,b   Tworoger, Shelley S ^a,b   Giovannucci, Edward ^a,b   Rosner, Bernard ^a,b   Ogino, Shuji ^a,b,f  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c NATIONAL CANCER CENTER   (Japan)

^d UNIVERSITY OF MICHIGAN   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Heterogeneity test; Molecular pathologic epidemiology; Omics; Pathogenesis; Pathology

Indexed keywords

ACETYLSALICYLIC ACID; CALCIUM; FOLIC ACID;

ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CALCIUM INTAKE; CANCER CLASSIFICATION; CANCER INCIDENCE; CANCER RISK; CANCER SCREENING; CASE CONTROL STUDY; COHORT ANALYSIS; COLORECTAL CANCER; COLORECTAL POLYP; COMPUTER PROGRAM; DISEASE ASSOCIATION; DRUG USE; EPIDEMIOLOGICAL DATA; FAMILY HISTORY; FOOD INTAKE; HUMAN; MOLECULAR PATHOLOGY; PHYSICAL ACTIVITY; SMOKING; STATISTICAL ANALYSIS; STATISTICAL MODEL; STUDY DESIGN; CLASSIFICATION; DISEASES; PROSPECTIVE STUDY;

CASE-CONTROL STUDIES; DISEASE; HUMANS; MODELS, STATISTICAL; PATHOLOGY, MOLECULAR; PROSPECTIVE STUDIES;

EID: 84956582609     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.6793     Document Type: Article

References (99)

1. MacMahon B, Pugh TF. Epidemiologic Methods. Little, Brown: Boston, 1960.
2. Ogino S, Lochhead P, Chan AT, Nishihara R, Cho E, Wolpin BM, Meyerhardt JA, Meissner A, Schernhammer ES, Fuchs CS, Giovannucci E. Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease. Modern Pathology 2013; 26:465-484.
3. Begg CB. A strategy for distinguishing optimal cancer subtypes. International Journal of Cancer 2011; 129:931-937.
4. Begg CB, Zabor EC. Detecting and exploiting etiologic heterogeneity in epidemiologic studies. American Journal of Epidemiology 2012; 176:512-518.
5. Amaral AF, Mendez-Pertuz M, Munoz A, Silverman DT, Allory Y, Kogevinas M, Lloreta J, Rothman N, Carrato A, Rivas del Fresno M, Real FX, Malats N. Plasma 25-hydroxyvitamin D(3) and bladder cancer risk according to tumor stage and FGFR3 status: a mechanism-based epidemiological study. Journal of the National Cancer Institute 2012; 104:1897-1904.
6. Shen H, Fridley BL, Song H, Lawrenson K, Cunningham JM, Ramus SJ, Cicek MS, Tyrer J, Stram D, Larson MC, Kobel M, Ziogas A, Zheng W, Yang HP, Wu AH, Wozniak EL, Woo YL, Winterhoff B, Wik E, Whittemore AS, Wentzensen N, Weber RP, Vitonis AF, Vincent D, Vierkant RA, Vergote I, Van Den Berg D, Van Altena AM, Tworoger SS, Thompson PJ, Tessier DC, Terry KL, Teo SH, Templeman C, Stram DO, Southey MC, Sieh W, Siddiqui N, Shvetsov YB, Shu XO, Shridhar V, Wang-Gohrke S, Severi G, Schwaab I, Salvesen HB, Rzepecka IK, Runnebaum IB, Rossing MA, Rodriguez-Rodriguez L, Risch HA, Renner SP, Poole EM, Pike MC, Phelan CM, Pelttari LM, Pejovic T, Paul J, Orlow I, Omar SZ, Olson SH, Odunsi K, Nickels S, Nevanlinna H, Ness RB, Narod SA, Nakanishi T, Moysich KB, Monteiro AN, Moes-Sosnowska J, Modugno F, Menon U, McLaughlin JR, McGuire V, Matsuo K, Adenan NA, Massuger LF, Lurie G, Lundvall L, Lubinski J, Lissowska J, Levine DA, Leminen A, Lee AW, Le ND, Lambrechts S, Lambrechts D, Kupryjanczyk J, Krakstad C, Konecny GE, Kjaer SK, Kiemeney LA, Kelemen LE, Keeney GL, Karlan BY, Karevan R, Kalli KR, Kajiyama H, Ji BT, Jensen A, et al. Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nature Communications 2013; 4:1628.
7. Begg CB, Zabor EC, Bernstein JL, Bernstein L, Press MF, Seshan VE. A conceptual and methodological framework for investigating etiologic heterogeneity. Statistics In Medicine 2013; 32:5039-5052.
8. Ogino S, Chan AT, Fuchs CS, Giovannucci E. Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut 2011; 60:397-411.
9. Ogino S, Stampfer M. Lifestyle factors and microsatellite instability in colorectal cancer: the evolving field of molecular pathological epidemiology. Journal of the National Cancer Institute 2010; 102:365-367.
10. Ogino S, Lochhead P, Giovannucci E, Meyerhardt JA, Fuchs CS, Chan A. Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology. Oncogene 2014; 33:2949-2955.
11. Chen H, Taylor NP, Sotamaa KM, Mutch DG, Powell MA, Schmidt AP, Feng S, Hampel HL, Chapelle AD, Goodfellow PJ. Evidence for heritable predisposition to epigenetic silencing of MLH1. International Journal of Cancer 2007; 120:1684-1688.
12. Allan JM, Shorto J, Adlard J, Bury J, Coggins R, George R, Katory M, Quirke P, Richman S, Scott D, Scott K, Seymour M, Travis LB, Worrillow LJ, Bishop DT, Cox A. MLH1 -93G>A promoter polymorphism and risk of mismatch repair deficient colorectal cancer. International Journal of Cancer 2008; 123:2456-2459.
13. Campbell PT, Curtin K, Ulrich CM, Samowitz WS, Bigler J, Velicer CM, Caan B, Potter JD, Slattery ML. Mismatch repair polymorphisms and risk of colon cancer, tumour microsatellite instability and interactions with lifestyle factors. Gut 2009; 58:661-667.
14. Raptis S, Mrkonjic M, Green RC, Pethe VV, Monga N, Chan YM, Daftary D, Dicks E, Younghusband BH, Parfrey PS, Gallinger SS, McLaughlin JR, Knight JA, Bapat B. MLH1 -93G>A promoter polymorphism and the risk of microsatellite-unstable colorectal cancer. Journal of the National Cancer Institute 2007; 99:463-474.
15. Samowitz WS, Curtin K, Wolff RK, Albertsen H, Sweeney C, Caan BJ, Ulrich CM, Potter JD, Slattery ML. The MLH1-93 G>A promoter polymorphism and genetic and epigenetic alterations in colon cancer. Genes, Chromosomes & Cancer 2008; 47:835-844.
16. Ogino S, Hazra A, Tranah GJ, Kirkner GJ, Kawasaki T, Nosho K, Ohnishi M, Suemoto Y, Meyerhardt JA, Hunter DJ, Fuchs CS. MGMT germline polymorphism is associated with somatic MGMT promoter methylation and gene silencing in colorectal cancer. Carcinogenesis 2007; 28:1985-1990.
17. Hawkins NJ, Lee JH, Wong JJ, Kwok CT, Ward RL, Hitchins MP. MGMT methylation is associated primarily with the germline C>T SNP (rs16906252) in colorectal cancer and normal colonic mucosa. Modern Pathology 2009; 22:1588-1599.
18. Slattery ML, Curtin K, Anderson K, Ma KN, Ballard L, Edwards S, Schaffer D, Potter J, Leppert M, Samowitz WS. Associations between cigarette smoking, lifestyle factors, and microsatellite instability in colon tumors. Journal of the National Cancer Institute 2000; 92:1831-1836.
19. Satia JA, Keku T, Galanko JA, Martin C, Doctolero RT, Tajima A, Sandler RS, Carethers JM. Diet, lifestyle, and genomic instability in the north Carolina colon cancer study. Cancer Epidemiology, Biomarkers and Prevention 2005; 14:429-436.
20. Slattery ML, Curtin K, Sweeney C, Levin TR, Potter J, Wolff RK, Albertsen H, Samowitz WS. Diet and lifestyle factor associations with CpG island methylator phenotype and BRAF mutations in colon cancer. International Journal of Cancer 2007; 120:656-663.
21. Campbell PT, Jacobs ET, Ulrich CM, Figueiredo JC, Poynter JN, McLaughlin JR, Haile RW, Jacobs EJ, Newcomb PA, Potter JD, Le Marchand L, Green RC, Parfrey P, Younghusband HB, Cotterchio M, Gallinger S, Jenkins MA, Hopper JL, Baron JA, Thibodeau SN, Lindor NM, Limburg PJ, Martinez ME, Registry ftCCF. Case-control study of overweight, obesity, and colorectal cancer risk, overall and by tumor microsatellite instability status. Journal of the National Cancer Institute 2010; 102:391-400.
22. Kuchiba A, Morikawa T, Yamauchi M, Imamura Y, Liao X, Chan AT, Meyerhardt JA, Giovannucci E, Fuchs CS, Ogino S. Body mass index and risk of colorectal cancer according to fatty acid synthase expression in the nurses' health study. Journal of the National Cancer Institute 2012; 104:415-420.
23. Wu AH, Shibata D, Yu MC, Lai MY, Ross RK. Dietary heterocyclic amines and microsatellite instability in colon adenocarcinomas. Carcinogenesis 2001; 22:1681-1684.
24. Chia VM, Newcomb PA, Bigler J, Morimoto LM, Thibodeau SN, Potter JD. Risk of microsatellite-unstable colorectal cancer is associated jointly with smoking and nonsteroidal anti-inflammatory drug use. Cancer Research 2006; 66:6877-6883.
25. Samowitz WS, Albertsen H, Sweeney C, Herrick J, Caan BJ, Anderson KE, Wolff RK, Slattery ML. Association of smoking, CpG island methylator phenotype, and V600E BRAF mutations in colon cancer. Journal of the National Cancer Institute 2006; 98:1731-1738.
26. Poynter JN, Haile RW, Siegmund KD, Campbell PT, Figueiredo JC, Limburg P, Young J, Le Marchand L, Potter JD, Cotterchio M, Casey G, Hopper JL, Jenkins MA, Thibodeau SN, Newcomb PA, Baron JA. Associations between smoking, alcohol consumption, and colorectal cancer, overall and by tumor microsatellite instability status. Cancer Epidemiology, Biomarkers and Prevention 2009; 18:2745-2750.
27. Rozek LS, Herron CM, Greenson JK, Moreno V, Capella G, Rennert G, Gruber SB. Smoking, gender, and ethnicity predict somatic BRAF mutations in colorectal cancer. Cancer Epidemiology, Biomarkers and Prevention 2010; 19:838-843.
28. Limsui D, Vierkant RA, Tillmans LS, Wang AH, Weisenberger DJ, Laird PW, Lynch CF, Anderson KE, French AJ, Haile RW, Harnack LJ, Potter JD, Slager SL, Smyrk TC, Thibodeau SN, Cerhan JR, Limburg PJ. Cigarette smoking and colorectal cancer risk by molecularly defined subtypes. Journal of the National Cancer Institute 2010; 102:1012-1022.
29. Leng S, Bernauer AM, Hong C, Do KC, Yingling CM, Flores KG, Tessema M, Tellez CS, Willink RP, Burki EA, Picchi MA, Stidley CA, Prados MD, Costello JF, Gilliland FD, Crowell RE, Belinsky SA. The A/G allele of Rs16906252 predicts for MGMT methylation and is selectively silenced in premalignant lesions from smokers and in lung adenocarcinomas. Clinical Cancer Research 2011; 17:2014-2023.
30. Ahrendt SA, Decker PA, Alawi EA, Zhu Yr YR, Sanchez-Cespedes M, Yang SC, Haasler GB, Kajdacsy-Balla A, Demeure MJ, Sidransky D. Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer 2001; 92:1525-1530.
31. Riely GJ, Kris MG, Rosenbaum D, Marks J, Li A, Chitale DA, Nafa K, Riedel ER, Hsu M, Pao W, Miller VA, Ladanyi M. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clinical Cancer Research 2008; 14:5731-5734.
32. Riely GJ, Marks J, Pao W. KRAS mutations in non-small cell lung cancer. Proceedings of the American Thoracic Society 2009; 6:201-205.
33. Julin B, Bergkvist C, Wolk A, Akesson A. Cadmium in diet and risk of cardiovascular disease in women. Epidemiology 2013; 24:880-885.
34. Jeong I, Rhie J, Kim I, Ryu I, Jung PK, Park YS, Lim YS, Kim HR, Park SG, Im HJ, Lee MY, Won JU. Working hours and cardiovascular disease in korean workers: a case-control study. Journal of Occupational Health 2014; 55:385-391.
35. Doshi-Velez F, Ge Y, Kohane I. Comorbidity clusters in autism spectrum disorders: an electronic health record time-series analysis. Pediatrics 2014; 133:e54-e63.
36. Dandri M, Locarnini S. New insight in the pathobiology of hepatitis B virus infection. Gut 2012; 61(Suppl 1):i6-17.
37. Perez OD. Appreciating the heterogeneity in autoimmune disease: multiparameter assessment of intracellular signaling mechanisms. Annals of the New York Academy of Sciences 2005; 1062:155-164.
38. Takamoto M, Kaburaki T, Mabuchi A, Araie M, Amano S, Aihara M, Tomidokoro A, Iwase A, Mabuchi F, Kashiwagi K, Shirato S, Yasuda N, Kawashima H, Nakajima F, Numaga J, Kawamura Y, Sasaki T, Tokunaga K. Common variants on chromosome 9p21 are associated with normal tension glaucoma. PLoS One 2012; 7:e40107.
39. Field AE, Camargo JCA, Ogino S. The merits of subtyping obesity: one size does not fit all. The Journal of American Medicial Association 2013; 310:2147-2148.
40. Nguyen PL, Ma J, Chavarro JE, Freedman ML, Lis R, Fedele G, Fiore C, Qiu W, Fiorentino M, Finn S, Penney KL, Eisenstein A, Schumacher FR, Mucci LA, Stampfer MJ, Giovannucci E, Loda M. Fatty acid synthase polymorphisms, tumor expression, body mass index, prostate cancer risk, and survival. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010; 28:3958-3964.
41. Giovannucci EL, Liu Y, Leitzmann MF, Stampfer MJ, Willett WC. A prospective study of physical activity and incident and fatal prostate cancer. Archives of Internal Medicine 2005; 165:1005-1010.
42. Gates MA, Rosner BA, Hecht JL, Tworoger SS. Risk factors for epithelial ovarian cancer by histologic subtype. American Journal of Epidemiology 2010; 171:45-53.
43. Yang HP, Trabert B, Murphy MA, Sherman ME, Sampson JN, Brinton LA, Hartge P, Hollenbeck A, Park Y, Wentzensen N. Ovarian cancer risk factors by histologic subtypes in the NIH-AARP Diet and Health Study. International Journal of Cancer Journal International Du Cancer 2012; 131:938-948.
44. Kotsopoulos J, Terry KL, Poole EM, Rosner B, Murphy MA, Hecht JL, Crum CP, Missmer SA, Cramer DW, Tworoger SS. Ovarian cancer risk factors by tumor dominance, a surrogate for cell of origin. International journal of cancer. Journal international du cancer 2013; 133:730-739.
45. Poole EM, Merritt MA, Jordan SJ, Yang HP, Hankinson SE, Park Y, Rosner B, Webb PM, Cramer DW, Wentzensen N, Terry KL, Tworoger SS. Hormonal and reproductive risk factors for epithelial ovarian cancer by tumor aggressiveness. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2013; 22:429-437.
46. Ferrari P, McKay JD, Jenab M, Brennan P, Canzian F, Vogel U, Tjonneland A, Overvad K, Tolstrup JS, Boutron-Ruault MC, Clavel-Chapelon F, Morois S, Kaaks R, Boeing H, Bergmann M, Trichopoulou A, Katsoulis M, Trichopoulos D, Krogh V, Panico S, Sacerdote C, Palli D, Tumino R, Peeters PH, van Gils CH, Bueno-de-Mesquita B, Vrieling A, Lund E, Hjartaker A, Agudo A, Suarez LR, Arriola L, Chirlaque MD, Ardanaz E, Sanchez MJ, Manjer J, Lindkvist B, Hallmans G, Palmqvist R, Allen N, Key T, Khaw KT, Slimani N, Rinaldi S, Romieu I, Boffetta P, Romaguera D, Norat T, Riboli E. Alcohol dehydrogenase and aldehyde dehydrogenase gene polymorphisms, alcohol intake and the risk of colorectal cancer in the European Prospective Investigation into Cancer and Nutrition study. European Journal of Clinical Nutrition 2012; 66:1303-1308.
47. Goldbohm RA, Van den Brandt PA, Van't Veer P, Dorant E, Sturmans F, Hermus RJ. Prospective study on alcohol consumption and the risk of cancer of the colon and rectum in the Netherlands. Cancer Causes & Control 1994; 5:95-104.
48. Bagnardi V, Blangiardo M, La Vecchia C, Corrao G. A meta-analysis of alcohol drinking and cancer risk. British Journal of Cancer 2001; 85:1700-1705.
49. Moskal A, Norat T, Ferrari P, Riboli E. Alcohol intake and colorectal cancer risk: a dose-response meta-analysis of published cohort studies. International Journal of Cancer 2007; 120:664-671.
50. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. World Cancer Research Fund, American Institute for Cancer Research 2007.
51. Colditz GA, Winn DM. Criteria for the evaluation of large cohort studies: an application to the nurses' health study. Journal of the National Cancer Institute 2008; 100:918-925.
52. Colditz GA, Hankinson SE. The Nurses' Health Study: lifestyle and health among women. Nature Reviews Cancer 2005; 5:388-396.
53. Robison LL, Armstrong GT, Boice JD, Chow EJ, Davies SM, Donaldson SS, Green DM, Hammond S, Meadows AT, Mertens AC, Mulvihill JJ, Nathan PC, Neglia JP, Packer RJ, Rajaraman P, Sklar CA, Stovall M, Strong LC, Yasui Y, Zeltzer LK. The Childhood Cancer Survivor Study: a National Cancer Institute-supported resource for outcome and intervention research. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009; 27:2308-2318.
54. Colditz GA. Ensuring long-term sustainability of existing cohorts remains the highest priority to inform cancer prevention and control. Cancer Causes and Control 2010; 21:649-656.
55. Hughes LA, Williamson EJ, van Engeland M, Jenkins MA, Giles G, Hopper J, Southey M, Young J, Buchanan D, Walsh M, Van den Brandt PA, Goldbohm RA, Weijenberg MP, English DR. Body size and risk for colorectal cancers showing BRAF mutation or microsatellite instability: a pooled analysis. International Journal of Epidemiology 2012; 41:1060-1072.
56. Ogino S, Giovannucci E. Commentary: Lifestyle factors and colorectal cancer microsatellite instability - molecular pathological epidemiology science, based on unique tumour principle. International Journal of Epidemiology 2012; 41:1072-1074.
57. Kalbfleisch JD. Prentice RL. Wiley: The Statistical Analysis of Failure Time Data, 1980.
58. Prentice RL, Kalbfleisch JD, Peterson AV Jr, Flournoy N, Farewell VT, Breslow NE. The analysis of failure times in the presence of competing risks. Biometrics 1978; 34:541-554.
59. Breslow NE, Lubin JH, Marek P, Langholz B. Multiplicative models and cohort analysis. Journal of the American Statistical Association 1983; 78:1-12.
60. Korn EL, Graubard BI, Midthune D. Time-to-event analysis of longitudinal follow-up of a survey: choice of the time-scale. American Journal Of Epidemiology 1997; 145:72-80.
61. Commenges D, Letenneur L, Joly P, Alioum A, Dartigues JF. Modelling age-specific risk: application to dementia. Statistics In Medicine 1998; 17:1973-1988.
62. Therneau TM, Grambach PM. The counting process form of a Cox model. In The Counting Process Form of a Cox Model. Springer: New York, New York, 2000.
63. Anderson TW. Introduction to Multivariate Statistics. John Wiley and Sons: New York, NY, 1984.
64. Lunn M, McNeil D. Applying Cox regression to competing risks. Biometrics 1995; 51:524-532.
65. Vaeth M. On the use of Walds test in exponential-families. International Statistical Review 1985; 53:199-214.
66. Bhattacharjee S, Rajaraman P, Jacobs KB, Wheeler WA, Melin BS, Hartge P, Yeager M, Chung CC, Chanock SJ, Chatterjee N. A subset-based approach improves power and interpretation for the combined analysis of genetic association studies of heterogeneous traits. The American Journal of Human Genetics 2012; 90:821-835.
67. Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology 1990; 1:43-46.
68. Savitz DA, Olshan AF. Multiple comparisons and related issues in the interpretation of epidemiologic data - Reply. American Journal Of Epidemiology 1997; 145:85-85.
69. Savitz DA, Olshan AF. Multiple comparisons and related issues in the interpretation of epidemiologic data. American Journal of Epidemiology 1995; 142:904-908.
70. Goodman SN. Multiple comparisons, explained. American Journal of Epidemiology 1998; 147: 807-812; discussion 815.
71. Thomas DCSJ, Dewar R, Robins J, Goldberg M, Armstrong BG. The problem of multiple inference in studies designed to generate hypotheses. American Journal of Epidemiology 1985:1080-1095.
72. Thompson JR. Invited commentary: Re: "multiple comparisons and related issues in the interpretation of epidemiologic data". American Journal of Epidemiology 1998; 147:801-806.
73. Storey JD. The positive false discovery rate: a Bayesian interpretation and the q-value. Annals of Statistics 2003; 31:2013-2035.
74. Day RW, Quinn GP. Comparisons of treatments after an analysis of variance in ecology. Ecological Monographs 1989; 59:433-463.
75. Story JD. A direct approach to false discovery rates. Journal of the Royal Statistical Society, Series B 2002; 64:479-498.
76. Miettinen OS. Theoretical Epidemiology: Principles Of Occurrence Research In Medicine. Wiley: New York, 1985.
77. Breslow NE, Day NE. Statistical Methods in Cancer Research. Vol I: The Analysis of Case-Control Studies. IARC Scientific Publications: Lyon, 1980.
78. Ogino S, Nishihara R, Lochhead P, Imamura Y, Kuchiba A, Morikawa T, Yamauchi M, Liao X, Qian ZR, Sun R, Sato K, Kirkner GJ, Wang M, Spiegelman D, Meyerhardt JA, Schernhammer ES, Chan AT, Giovannucci E, Fuchs CS. Prospective study of family history and colorectal cancer risk by tumor LINE-1 methylation level. Journal of the National Cancer Institute 2013; 105:130-140.
79. Chatterjee N. A two-stage regression model for epidemiological studies with multivariate disease classification data. Journal of the American Statistical Association 2004; 99:127-138.
80. Chatterjee N, Sinha S, Diver WR, Feigelson HS. Analysis of cohort studies with multivariate and partially observed disease classification data. Biometrika 2010; 97:683-698.
81. Rosner B, Glynn RJ, Tamimi RM, Chen WY, Colditz GA, Willett WC, Hankinson SE. Breast cancer risk prediction with heterogeneous risk profiles according to breast cancer tumor markers. American Journal of Epidemiology 2013; 15:296-308.
82. Wang M, Kuchiba A, Ogino S. A meta-regression method for studying etiological heterogeneity across disease subtypes classified by multiple biomarkers. American Journal Of Epidemiology 2015; 182:263-270.
83. Stram DO. Meta-analysis of published data using a linear mixed-effects model. Biometrics 1996; 52:536-544.
84. Hedges LV, Vevea JL. Fixed- and random-effects models in meta-analysis. Psychological Methods 1998; 3:486-504.
85. Ritz J, Demidenko E, Spiegelman D. Multivariate meta-analysis for data consortia, individual patient meta-analysis, and pooling projects. Journal of Statistical Planning and Inference 2008; 138:1919-1933.
86. van Houwelingen HC, Arends LR, Stijnen T. Advanced methods in meta-analysis: multivariate approach and meta-regression. Statistics In Medicine 2002; 21:589-624.
87. Schernhammer ES, Giovannucci E, Kawasaki T, Rosner B, Fuchs CS, Ogino S. Dietary folate, alcohol and B vitamins in relation to LINE-1 hypomethylation in colon cancer. Gut 2010; 59:794-799.
88. Ury HK. Efficiency of case-control studies with multiple controls per case: continuous or dichotomous data. Biometrics 1975; 31:643-649.
89. Langholz B, Goldstein L. Conditional logistic analysis of case-control studies with complex sampling. Biostatistics 2001; 2:63-84.
90. Viechtbauer W. Conducting meta-analyses in R with the metafor package. Journal of Statistical Software 2010; 36:1-48.
91. Begg CB, Seshan VE, Zabor EC, Furberg H, Arora A, Shen R, Maranchie JK, Nielsen ME, Rathmell WK, Signoretti S, Tamboli P, Karam JA, Choueiri TK, Hakimi AA, Hsieh JJ. Genomic investigation of etiologic heterogeneity: methodologic challenges. BMC Medical Research Methodology 2014; 14:138-147.
92. Wei LJ, Lin DY, Weissfeld L. Regression-analysis of multivariate incomplete failure time data by modeling marginal distributions. Journal of the American Statistical Association 1989; 84:1065-1073.
93. Colussi D, Brandi G, Bazzoli F, Ricciardiello L. Molecular pathways involved in colorectal cancer: implications for disease behavior and prevention. International Journal of Molecular Sciences 2013; 14:16365-16385.
94. Bishehsari F, Mahdavinia M, Vacca M, Malekzadeh R, Mariani-Costantini R. Epidemiological transition of colorectal cancer in developing countries: environmental factors, molecular pathways, and opportunities for prevention. World journal of gastroenterology: WJG 2014; 20:6055-6072.
95. Barrow TM, Michels KB. Epigenetic epidemiology of cancer. Biochemical and Biophysical Research Communications 2014; 455:70-83.
96. Ogino S CP, Nishihara R, Phipps AI, Beck AH, Sherman ME, Chan AT, Troester MA, Bass AJ, Fitzgerald KC, Irizarry RA, Kelsey KT, Nan H, Peters U, Poole EM, Qian ZR, Tamimi RM, Tchetgen Tchetgen EJ, Tworoger SS, Zhang X, Giovannucci EL, van den Brandt PA, Rosner BA, Wang M, Chatterjee N, Begg CB. Proceedings of the Second International Molecular Pathological Epidemiology (MPE) Meeting. Cancer causes Cont. In press, 2015.
97. Ogino S, Nishihara R, VanderWeele TJ, Wang M, Nishi A, Lochhead P, Qian ZR, Zhang X, Wu K, Nan H, Yoshida K, Milner DA Jr, Chan AT, Field AE, Camargo CA Jr, Williams MA, Giovannucci E. Molecular pathological epidemiology is essential in studying neoplastic and non-neoplastic diseases in the era of precision medicine. Epidemiology In press, 2015.
98. Collins FS, Varmus H. A new initiative on precision medicine. New England Journal of Medicine 2015; 372:793-795.
99. Bayer R, Galea S. Public health in the precision-medicine era. New England Journal of Medicine 2015; 373:499-501.